Dataset Information

Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization.

ABSTRACT:

Purpose

To assess the 5-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization.

Methods

Retrospective, multicenter, consecutive case series of eight patients with inflammatory ocular neovascularization refractory to standard therapy who were treated with intravitreal bevacizumab and followed for 5 years after first injection. The outcome measures included improvement of best-corrected visual acuity expressed as logarithm of minimum angle of resolution.

Results

Mean best-corrected visual acuity significantly improved from 0.58 at baseline (6/23 or 20/76; standard deviation = 0.32) to 0.20 at final assessment (6/10 or 20/32; standard deviation = 0.25) (n = 8; P = 0.02), a gain of 3.8 lines (median: three injections; eight eyes; eight patients). No ocular or systemic complications from intravitreal bevacizumab were noted.

Conclusion

At 5 years, intravitreal bevacizumab sustained significant visual improvement in ocular neovascularization due to a variety of inflammatory ocular diseases without major complications after a median of three injections.

SUBMITTER: Mansour AM

PROVIDER: S-EPMC3422149 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization.

Mansour Ahmad M AM Mackensen Friederike F Mahendradas Padmamalini P Khairallah Moncef M Lai Timothy Yy TY Bashshur Ziad Z

Clinical ophthalmology (Auckland, N.Z.) 20120801

<h4>Purpose</h4>To assess the 5-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization.<h4>Methods</h4>Retrospective, multicenter, consecutive case series of eight patients with inflammatory ocular neovascularization refractory to standard therapy who were treated with intravitreal bevacizumab and followed for 5 years after first injection. The outcome measures included improvement of best-corrected visual acuity expressed as logarithm of minimum angle of resol ...[more]

PMID: 22927733

Similar Datasets

Project description:BackgroundTo explore the association of clinical characteristics and retinal microstructural features on optical coherence tomography in predicting 1-year visual response following intravitreal bevacizumab injections in eyes with visual impairment from center-involved diabetic macular edema (CI-DME).MethodsMedical records of patients with visual impairment from CI-DME, who initiated intravitreal bevacizumab injections between Jan 2012 and Dec 2016 and were followed for a minimum of 12 months were retrospectively reviewed.ResultsThe study included 226 eyes with a mean (SD) baseline visual acuity (VA) of 51.8 (19.1) letters. At week 12, following the three initial treatments, a mean (SD) VA improved to 61.7 (17.8) letters. Visual gain ≥ 10 letters was observed in 109 eyes (48.2%), while a limited early visual gain < 5 letters was noted in 80 eyes (35.4%). At one year, 110 eyes (48.7%) achieved a good VA gain ≥ 10 letters. In addition, eyes with poor baseline VA had a higher proportion of eyes that obtained limited early VA gained at week 12 (< 5 letters) and maintained in this visual response category at moth 12 compared to eyes with better baseline VA (74.1% versus 59.1%). In the multivariable logistic regression, the following factors reduced the probability of 1-year visual gain ≥ 10 letters: elderly (p = 0.040), better baseline vision (p = 0.001), and limited early visual gain < 5 letters at week 12 (p < 0.001). In multivariable linear regression, male (p = 0.010) and eyes with the presence of hyperreflective foci on baseline OCT (p = 0.010) were likely to have higher VA improvement. However, eyes with better baseline VA (p = 0.002), limited early VA gain at week 12 (p < 0.001), and a presence of EZ disruption at week 12 (p = 0.002) were likely to have less VA improvement.ConclusionsAlthough bevacizumab is considered as effective management for CI-DME, variability in treatment responses is expected. This study revealed that baseline characteristics and visual responses at week 12 might help predict the long-term treatment response. Eyes with characteristics at risk of limited long-term visual outcome may require attention in optimizing their individual treatment strategies.

Dataset Information

Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization.

Purpose

Methods

Results

Conclusion

Publications

Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets